Malignant Melanoma Treatment Market Report 2026

Malignant Melanoma Treatment Market Overview

• Malignant Melanoma Treatment market size has reached to $7.98 billion in 2025 • Expected to grow to $13.37 billion in 2030 at a compound annual growth rate (CAGR) of 11.1% • Growth Driver: Increasing Incidence Of Melanoma To Fuel The Growth In Malignant Melanoma Treatment Market • Market Trend: Advanced Immunotherapies To Address Unmet Needs In Melanoma Care • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Malignant Melanoma Treatment Market?

Malignant melanoma treatment refers to the medical interventions and therapies aimed at managing and potentially curing malignant melanoma, a type of skin cancer that develops from melanocytes, the cells responsible for producing the skin pigment melanin. The treatment of malignant melanoma offers several advantages critical for the well-being and potential recovery of individuals diagnosed with this aggressive form of skin cancer. The main treatments for malignant melanoma are immunotherapy, radiation therapy, chemotherapy, and others. Immunotherapy is a type of medical treatment that harnesses the body's own immune system to fight diseases, including certain types of cancer. It is indicated for the treatment of lentigo malignant melanoma, acral lentiginous melanoma, nodular melanoma, and superficial spreading melanoma used by various end-users such as hospitals, specialty clinics, and others.

What Is The Malignant Melanoma Treatment Market Growth Forecast?

The malignant melanoma treatment market size is expected to see rapid growth in the next few years. It will grow to $13.37 billion in 2030 at a compound annual growth rate (CAGR) of 11.1%. The growth in the forecast period can be attributed to increasing approval of advanced immunotherapies, growing emphasis on personalized cancer treatment, rising investment in oncology research and development, expansion of melanoma screening programs, increasing healthcare access in emerging markets. Major trends in the forecast period include rising adoption of immunotherapy-based treatments, growing use of combination treatment regimens, increasing focus on early-stage melanoma intervention, expansion of clinical trials for novel melanoma therapies, higher demand for specialized oncology care centers.

Global Malignant Melanoma Treatment Market Segmentation

1) By Treatment: Immunotherapy, Radiation Therapy, Chemotherapy, Other Treatments 2) By Disease Type: Lentigo Maligna Melanoma, Acral Lentiginous Melanoma, Nodular Melanoma, Superficial Spreading Melanoma 3) By End-User: Hospitals, Specialty Clinics, Other End Users Subsegments: 1) By Immunotherapy: Checkpoint Inhibitors, Cytokine Therapy, Oncolytic Virus Therapy 2) By Radiation Therapy: External Beam Radiation Therapy, Stereotactic Radiation Therapy 3) By Chemotherapy: Traditional Chemotherapy Agents, Combination Chemotherapy Regimens 4) By Other Treatments: Targeted Therapy, Surgical Interventions, Clinical Trials For Novel Therapies

What Is The Driver Of The Malignant Melanoma Treatment Market?

The increasing incidence of melanoma is expected to propel the growth of the malignant melanoma treatment market going forward. Melanoma is a form of skin cancer that begins in melanocytes, the skin cells responsible for pigment production. Treatment for melanoma often involves surgical removal of the tumor, and additional therapies like immunotherapy or targeted therapy may be recommended based on the stage and extent of the cancer. For instance, in February 2023, according to the Melanoma Research Foundation, a US-based organization, the total number of cases of melanoma in the United States in 2023 was 1,87,000 which increased by 7.3% and reached 2,00,651 in 2024. Therefore, the increasing incidence of melanoma is driving the growth of the malignant melanoma treatment industry.

Key Players In The Global Malignant Melanoma Treatment Market

Major companies operating in the malignant melanoma treatment market are Johnson & Johnson Private Limited, Pfizer Inc., Hoffmann-La Roche AG, Bayer AG, Novartis AG, Merck & Co. Inc., GlaxoSmithKline plc, Bristol-Myers Squibb Company, Sanofi S.A., AstraZeneca plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Daiichi Sankyo Company Limited, Mylan N.V., Chugai Pharmaceutical Co. Ltd., Sun Pharmaceutical Industries Limited, Ono Pharmaceutical Co. Ltd., Exelixis Inc., Array BioPharma Inc., Pierre Fabre Group, Clinigen Group, Iovance Biotherapeutics Inc., X4 Pharmaceuticals Inc., Mirati Therapeutics Inc., Moleculin Biotech Inc., Polynoma LLC, Enzon Pharmaceuticals Inc., Northwest Biotherapeutics Inc.

Global Malignant Melanoma Treatment Market Trends and Insights

Major companies operating in the malignant melanoma treatment market are focusing on developing innovative solutions, such as autologous tumor-infiltrating lymphocyte (TIL) therapies, to meet the rising demand for effective post-checkpoint immunotherapies and personalized cell-based options for patients who progress after PD-1 inhibitors and targeted therapies. Autologous tumor-infiltrating lymphocyte (TIL) therapy is a type of immunotherapy where a patient’s own immune cells that have infiltrated their tumor are collected, expanded in the lab, and reinfused to help the body target and destroy cancer cells more effectively. For instance, in February 2024, Iovance Biotherapeutics, a US-based biopharmaceutical company, launched AMTAGVI (lifileucel), an autologous TIL therapy for adults with unresectable or metastatic melanoma who have progressed after prior PD-1 therapy (and targeted therapy if BRAF V600-mutant). AMTAGVI (lifileucel) is composed of expanded tumor-infiltrating lymphocytes harvested from the patient’s own tumor and reinfused after conditioning; it functions by amplifying tumor-reactive T cells to mediate tumor cell killing. The therapy’s unique features include individualized manufacturing, a single-administration treatment paradigm, and the potential to recognize multiple tumor antigens.

What Are Latest Mergers And Acquisitions In The Malignant Melanoma Treatment Market?

In October 2023, Bristol-Myers Squibb Company, a US-based biopharmaceutical company, acquired Mirati Therapeutics, Inc. for an undisclosed amount. With this acquisition, Bristol-Myers Squibb Company aimed to strengthen and diversify its oncology portfolio by adding an approved KRAS G12C inhibitor and complementary clinical-stage assets to accelerate growth and combination strategies. Mirati Therapeutics, Inc. is a US-based biotechnology company that specializes in discovering and developing targeted oncology therapies, notably KRAZATI (adagrasib), a KRAS G12C inhibitor, and a pipeline of KRAS- and PRMT5-targeting candidates.

Regional Outlook

North America was the largest region in the malignant melanoma treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Malignant Melanoma Treatment Market?

The malignant melanoma treatment market consists of revenues earned by entities by providing services such as diagnosis and staging services, surgical services, medical treatments, genetic counseling, aesthetic services, and cosmetic services. The market value includes the value of related goods sold by the service provider or included within the service offering. The malignant melanoma treatment market also includes sales of aldesleukin, binimetinib, braftovi (encorafenib), cobimetinib fumarate, cotellic (cobimetinib fumarate), dabrafenib mesylate, dacarbazine, and encorafenib. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Malignant Melanoma Treatment Market Report 2026?

The malignant melanoma treatment market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the malignant melanoma treatment industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.